Amgen Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +75

Amgen (Nasdaq:AMGN) - Stock Analysis - Simply Wall St

Drug approval New drug indication AI-generated analysis

πŸ“ˆ Amgen presented new data at the American Heart Association Scientific Sessions 2026 supporting earlier Repatha use for high-risk cardiovascular patients.

πŸ’Š The findings show Repatha is highly cost-effective and beneficial for patients without prior heart attacks or strokes, as well as those with chronic kidney disease.

βœ… These results align with U.S. FDA and European Commission approvals from August 2025 that expanded Repatha's eligible patient pool.

πŸ“Š Amgen shares trade at $465.23, up 42.0% year to date, reflecting market confidence in the growing addressable market for Repatha.

⏳ The key challenge is determining how quickly physicians will adopt earlier Repatha use across these expanded indications.

πŸ’° Real-world uptake of these new indications will directly influence revenue concentration within Amgen's cardiovascular portfolio.

Bullish Signals
  • Amgen presented new data at the American Heart Association Scientific Sessions 2026 showing Repatha is highly cost-effective and beneficial when used earlier for high-risk cardiovascular patients.
  • The findings align with U.S. FDA and European Commission approvals from August 2025 that expanded Repatha's eligible patient pool to include those without prior heart attacks or strokes.
  • Amgen shares are trading at $465.23, up 42.0% year to date, reflecting strong market valuation of the business as Repatha's addressable market grows.
Full Analysis
Amgen presented new clinical data at the American Heart Association Scientific Sessions 2026 supporting earlier use of its blockbuster drug Repatha for high-risk cardiovascular patients. The findings demonstrate that the therapy is highly cost-effective and beneficial for individuals without prior heart attacks or strokes, as well as those with chronic kidney disease. These results align with regulatory approvals received in August 2025 from both the U.S. FDA and the European Commission, which have significantly widened Repatha's indications. This expansion effectively increases the eligible patient pool and reinforces the strategy of intensive LDL-C lowering across a broader risk spectrum within Amgen's cardiovascular portfolio. Amgen shares are currently trading at $465.23, reflecting a 42.0% year-to-date gain as the market values the business based on the growing addressable market for Repatha. The primary focus now is on the speed of physician adoption for these expanded indications, as real-world uptake will determine how much this regulatory and clinical backing translates into tangible revenue concentration.